Business Context and Reporting Period
This Form 6-K was filed by Morria Biopharmaceuticals PLC (commonly known as Celsus Therapeutics) on May 8, 2013. The filing serves to announce positive Phase II interim results for the Company's drug candidate MRX-6 in the treatment of contact dermatitis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the announcement of positive interim results from a Phase II clinical trial for MRX-6. No financial changes versus prior periods are disclosed in this document.
Outlook and Management Commentary
Management highlighted the positive interim results for MRX-6 as a significant development. The full press release detailing these results is filed as Exhibit 99.1 and incorporated by reference. No specific financial guidance, risk factors, or contingencies are detailed within the body of this Form 6-K.
Key Facts for Investors to Verify
- Review Exhibit 99.1 (Press Release dated May 8, 2013) for specific data points regarding the Phase II interim results for MRX-6.
- Confirm the current corporate name usage, as the registrant is Morria Biopharmaceuticals PLC but is commonly known as Celsus Therapeutics.
- Check subsequent filings for financial updates, as this document contains no financial data.